| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -33,068 | -15,614 |
| Stock-based compensation | 2,625 | 1,809 |
| Depreciation | 40 | 27 |
| Fair value change in warrant and other derivative liabilities | -5,803 | 3,722 |
| Non-cash interest | 68 | - |
| Unrealized loss from short-term investments | -2 | -2 |
| Warrant financing costs | 1,337 | 1,337 |
| Accounts receivable | -647 | -164 |
| Contract assets and unbilled receivables | -845 | -1,031 |
| Prepaids and other current assets | 300 | 918 |
| Accounts payable | -797 | -1,703 |
| Accrued expenses | -2,622 | -1,676 |
| Net cash used in operating activities | -25,420 | -19,263 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from issuance of common stock and pre-funded warrants in connection with the march 2025 offering and march 2025 private placement | 5,980 | 5,980 |
| Proceeds from issuance of warrants in connection with the march 2025 offering and march 2025 private placement | 15,520 | 15,520 |
| Proceeds from issuance of common stock in connection with the at-the-market program, private placement and purchase agreement | 5,626 | 409 |
| Proceeds from funding agreement, related party | 1,000 | 1,000 |
| Issuance costs | 2,203 | 1,507 |
| Exercise of stock options | 27 | 5 |
| Share repurchases for the payment of employee taxes | 36 | 36 |
| Net cash provided by financing activities | 25,914 | 21,371 |
| Net increase (decrease) in cash and cash equivalents | 494 | 2,108 |
| Cash and cash equivalents at beginning of period | 30,321 | - |
| Cash and cash equivalents at end of period | 30,815 | - |
Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. (IRD)